JP2011506476A5 - - Google Patents

Download PDF

Info

Publication number
JP2011506476A5
JP2011506476A5 JP2010538191A JP2010538191A JP2011506476A5 JP 2011506476 A5 JP2011506476 A5 JP 2011506476A5 JP 2010538191 A JP2010538191 A JP 2010538191A JP 2010538191 A JP2010538191 A JP 2010538191A JP 2011506476 A5 JP2011506476 A5 JP 2011506476A5
Authority
JP
Japan
Prior art keywords
region
sialic acid
terminal sialic
composition
linked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010538191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011506476A (ja
Filing date
Publication date
Priority claimed from US11/957,015 external-priority patent/US20080206246A1/en
Application filed filed Critical
Publication of JP2011506476A publication Critical patent/JP2011506476A/ja
Publication of JP2011506476A5 publication Critical patent/JP2011506476A5/ja
Withdrawn legal-status Critical Current

Links

JP2010538191A 2007-12-14 2008-12-12 抗炎症性が促進しかつ細胞毒性が低減したポリペプチドおよび関連する方法 Withdrawn JP2011506476A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/957,015 US20080206246A1 (en) 2006-04-05 2007-12-14 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
PCT/US2008/086622 WO2009079382A1 (en) 2007-12-14 2008-12-12 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods

Publications (2)

Publication Number Publication Date
JP2011506476A JP2011506476A (ja) 2011-03-03
JP2011506476A5 true JP2011506476A5 (enExample) 2012-02-02

Family

ID=40796321

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010538191A Withdrawn JP2011506476A (ja) 2007-12-14 2008-12-12 抗炎症性が促進しかつ細胞毒性が低減したポリペプチドおよび関連する方法

Country Status (11)

Country Link
US (1) US20080206246A1 (enExample)
EP (1) EP2227255A4 (enExample)
JP (1) JP2011506476A (enExample)
CN (1) CN101896202A (enExample)
AU (1) AU2008338550A1 (enExample)
CA (1) CA2707304A1 (enExample)
EA (1) EA201070739A1 (enExample)
IL (1) IL206029A0 (enExample)
MX (1) MX2010006537A (enExample)
WO (1) WO2009079382A1 (enExample)
ZA (1) ZA201004045B (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470318B2 (en) * 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
AU2007235413B2 (en) * 2006-04-05 2012-08-02 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20110150867A1 (en) * 2007-12-14 2011-06-23 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
JP2011517960A (ja) * 2008-04-22 2011-06-23 ザ ロックフェラー ユニバーシティー 抗炎症化合物の識別方法
EP2233499A1 (en) 2009-03-26 2010-09-29 CSL Behring AG Antibody composition with altered Fab sialylation
US9187568B2 (en) 2009-05-07 2015-11-17 Stallergenes S.A. Use of IgG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and manifestations via the mucosal route
RU2579977C2 (ru) 2009-11-13 2016-04-10 Грифольс Терапьютикс Инк. СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
US20130058917A1 (en) * 2010-05-07 2013-03-07 Fabian Käsermann Antibody composition obtained by fractionation of plasma immunoglobulins affinity chromatography on a sambucus nigra affinity column
AU2011258425B2 (en) 2010-05-27 2015-12-10 Merck Sharp & Dohme Llc Method for preparing antibodies having improved properties
AR085302A1 (es) * 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
AU2012258907A1 (en) * 2011-05-25 2013-11-07 Merck Sharp & Dohme Corp. Method for preparing Fc-containing polypeptides having improved properties
KR20140097245A (ko) * 2011-10-31 2014-08-06 머크 샤프 앤드 돔 코포레이션 개선된 특성을 갖는 항체의 제조 방법
EP2780463A4 (en) * 2011-11-18 2015-07-01 Merck Sharp & Dohme FC-CONTAINING POLYPEPTIDES WITH INCREASED INFLAMMATORY FEATURES AND INCREASED FCRN BINDING
US12384848B2 (en) * 2011-12-19 2025-08-12 The Rockefeller University Anti-inflammatory polypeptides
EA201892339A3 (ru) 2011-12-19 2019-06-28 Дзе Рокфеллер Юниверсити Несиалированный выделенный полипептид, способ получения указанного полипептида и фармацевтическая композиция для лечения воспалительного заболевания
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2014018747A2 (en) 2012-07-26 2014-01-30 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CA2888519C (en) 2012-10-17 2023-02-21 Liverpool School Of Tropical Medicine Immunomodulatory proteins
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
CN114717206A (zh) 2013-03-15 2022-07-08 Atyr 医药公司 组氨酰-trna合成酶-fc缀合物
ES2708759T3 (es) 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedimientos para el tratamiento de la neurodegeneración
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
EP3058084A4 (en) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US11015215B2 (en) * 2014-01-09 2021-05-25 The Johns Hopkins University Use of high flux SCFA-derivatized monosaccharides in recombinant glycoprotein production
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ７３に対する抗体およびその使用
ES2826566T3 (es) 2014-11-21 2021-05-18 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas
AR103268A1 (es) 2014-12-23 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra tigit
AU2016271111B2 (en) 2015-05-29 2022-04-28 Bristol-Myers Squibb Company Antibodies against OX40 and uses thereof
MX2017016502A (es) 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
FR3038517B1 (fr) * 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
AU2017228470A1 (en) 2016-03-04 2018-08-30 Bristol-Myers Squibb Company Combination therapy with anti-CD73 antibodies
CN116063494A (zh) 2016-03-04 2023-05-05 洛克菲勒大学 具有增强的激动剂活性的cd40的抗体
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
ES2994451T3 (en) 2017-04-20 2025-01-24 Atyr Pharma Inc Compositions for treating lung inflammation
MX2019013132A (es) 2017-05-25 2020-01-27 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas.
EA202091521A1 (ru) 2017-12-19 2020-10-22 Дзе Рокфеллер Юниверсити ВАРИАНТЫ ДОМЕНА Fc IgG ЧЕЛОВЕКА С УЛУЧШЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
CN111788227B (zh) 2017-12-27 2025-02-25 百时美施贵宝公司 抗cd40抗体及其用途
WO2019195770A1 (en) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
AU2019312366B2 (en) 2018-07-26 2025-08-14 Atyr Pharma, Inc. Compositions and methods for treating NRP2-associated diseases
MX2021005708A (es) 2018-11-16 2021-09-21 Bristol Myers Squibb Co Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
JP2022513653A (ja) 2018-11-28 2022-02-09 ブリストル－マイヤーズ スクイブ カンパニー 修飾された重鎖定常領域を含む抗体
AU2020358854B2 (en) 2019-10-03 2026-08-13 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
KR102549282B1 (ko) * 2019-11-18 2023-06-30 건국대학교 산학협력단 시알산화된 면역글로불린을 유효성분으로 포함하는 염증성 질환의 치료용 조성물
MX2022010826A (es) * 2020-03-05 2022-12-02 Momenta Pharmaceuticals Inc Métodos para elaborar inmunoglobulina hipersialilada.
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
JP2024532620A (ja) 2021-08-30 2024-09-05 ラッセン・セラピューティクス１・インコーポレイテッド 抗ＩＬ－１１Ｒα抗体
WO2023104128A1 (zh) * 2021-12-09 2023-06-15 上海宝济药业有限公司 具有改变的糖基化修饰的Fc多肽
WO2024148240A1 (en) 2023-01-06 2024-07-11 Lassen Therapeutics 1, Inc. ANTI-IL-11Rα ANTIBODIES FOR TREATING THYROID EYE DISEASE
TW202430560A (zh) 2023-01-06 2024-08-01 美商拉森醫療公司 抗ｉｌ－１８ｂｐ抗體
EP4646433A1 (en) 2023-01-06 2025-11-12 Lassen Therapeutics, Inc. Anti-il-18bp antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2556219B1 (fr) * 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
AU656934B2 (en) * 1990-11-23 1995-02-23 General Hospital Corporation, The Inhibition of cell adhesion protein-carbohydrate interactions
ES2378272T3 (es) * 1999-04-15 2012-04-10 Crucell Holland B.V. Producción de proteína recombinante en una célula humana
DE19927835A1 (de) * 1999-06-18 2000-12-21 Clariant Gmbh Verwendung von verbesserten Cyanpigmenten in elektrophotographischen Tonern und Entwicklern, Pulverlacken und Ink-Jet-Tinten
US7064191B2 (en) * 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US7427469B2 (en) * 2002-11-05 2008-09-23 Institut Pasteur Method of treating cytomegalovirus with DC-SIGN blockers
US20070048740A1 (en) * 2003-02-14 2007-03-01 Research Association For Biotechnology Full-length cDNA
US7155641B2 (en) * 2003-05-15 2006-12-26 Microsoft Corporation System and method for monitoring the performance of a server
HUE038955T2 (hu) * 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
AU2004299053B2 (en) * 2003-12-15 2011-01-06 Alexion Pharmaceuticals, Inc. Novel anti-DC-SIGN antibodies
WO2007024743A2 (en) * 2005-08-19 2007-03-01 Centocor, Inc. Proteolysis resistant antibody preparations
AU2006312148B2 (en) * 2005-11-07 2012-04-12 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
WO2008057634A2 (en) * 2006-10-26 2008-05-15 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
AU2007235413B2 (en) * 2006-04-05 2012-08-02 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
JP2009087163A (ja) * 2007-10-01 2009-04-23 Brother Ind Ltd ジョブ実行装置及びジョブ実行方法

Similar Documents

Publication Publication Date Title
EP2953971B1 (en) Il-11r binding proteins and uses thereof
CN104144700B (zh) 抗CD1d的抗体
JP2008512988A5 (enExample)
KR20050033563A (ko) 포유동물 ｅｐｏ 모방 ｃｈ1 결실된 모방체, 조성물, 방법및 용도
CN111655717A (zh) IL-22 Fc融合蛋白及使用方法
KR20060117930A (ko) 인간 ｅｐｏ 미메틱 힌지 코어 미메티바디, 조성물, 방법및 용도
JP2018504911A (ja) 治療及び診断剤
JP2011506476A (ja) 抗炎症性が促進しかつ細胞毒性が低減したポリペプチドおよび関連する方法
JP2022525754A5 (enExample)
US9731007B2 (en) Tumour necrosis factor receptor fusion proteins and methods of using the same
EP2411417A1 (en) Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
JP2024505072A (ja) イヌ科動物抗体の定常領域における変異
CN120787235A (zh) Sars-cov-2棘蛋白特异性抗体及其用途
JP2024503212A (ja) ネコ科動物抗体の定常領域における変異
US20250230210A1 (en) Long-acting granulocyte macrophage-colony stimulating factor
JP2023551194A (ja) ウシ科動物抗体バリアント
JP2009508476A5 (enExample)
JP2023543262A (ja) イヌ科動物抗体バリアント
JP7173866B2 (ja) コンジュゲートされたｃ１エステラーゼインヒビター及びその使用
US20240076410A1 (en) Fc-engineered anti-human ige antibodies and methods of use
JP6882440B2 (ja) 抗ｉｌ４−ｉｌ１３二重特異性抗体
TW202604967A (zh) 經修飾之Ｆｃ多肽
TW202227473A (zh) Ｇｌｐ１－ｇｃｇｒ抗體融合蛋白變體及包含其的組成物
WO2025049818A1 (en) Tnfr1 antagonists lacking agonist activity and uses thereof
TW202600604A (zh) Ghr激動型抗體及其應用